AMRN Share Price

Open 3.44 Change Price %
High 3.52 1 Day 0.03 0.86
Low 3.44 1 Week 0.19 5.72
Close 3.51 1 Month 0.56 18.98
Volume 1257755 1 Year 2.15 158.09
52 Week High 3.65
52 Week Low 1.34
AMRN Important Levels
Resistance 2 3.58
Resistance 1 3.55
Pivot 3.49
Support 1 3.47
Support 2 3.44
NASDAQ USA Most Active Stocks
FNFG 10.18 -0.20%
ASTI 0.00 0.00%
DELL 13.86 0.22%
RFMD 16.59 -2.07%
RIMM 13.03 0.39%
BBEP 0.12 0.00%
GTAT 0.44 0.00%
SUSQ 14.20 -0.77%
ACAS 17.99 0.39%
CSCO 33.74 0.42%
More..
NASDAQ USA Top Gainers Stocks
EDMC 0.02 100.00%
LIWA 0.02 100.00%
QKLS 0.20 100.00%
MOSY 3.50 54.19%
LOCM 0.09 50.00%
MYRX 0.06 50.00%
LMIA 13.66 48.64%
CPSL 0.10 42.86%
WRES 0.09 28.57%
BSDM 0.62 26.53%
More..
NASDAQ USA Top Losers Stocks
GPRC 0.00 -100.00%
TXCC 0.01 -95.00%
HCIIP 10.10 -67.52%
CRMB 0.27 -57.81%
KIOR 0.03 -57.14%
QTWW 0.08 -50.00%
SPIR 0.01 -50.00%
OSH 0.26 -49.02%
OSH 0.26 -49.02%
DVOX 0.05 -44.44%
More..

Amarin Corporation PLC (NASDAQ: AMRN)

AMRN Technical Analysis 5
As on 17th Feb 2017 AMRN Share Price closed @ 3.51 and we RECOMMEND Strong Buy for LONG-TERM with Stoploss of 2.64 & Strong Buy for SHORT-TERM with Stoploss of 3.12 we also expect STOCK to react on Following IMPORTANT LEVELS.
AMRN Target for February
1st Target up-side 3.21
2nd Target up-side 3.38
3rd Target up-side 3.55
1st Target down-side 2.73
2nd Target down-side 2.56
3rd Target down-side 2.39
AMRN Other Details
Segment EQ
Market Capital 1595353216.00
Sector Healthcare
Industry Drug Manufacturers - Other
Offical website http://www.amarincorp.com
AMRN Address
AMRN
2 Pembroke House
Upper Pembroke Street 28-32
Dublin, 2
Ireland
Phone: 353 1 669 9020
Interactive Technical Analysis Chart Amarin Corporation PLC ( AMRN NASDAQ USA )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on Amarin Corporation PLC
AMRN Business Profile
Amarin Corporation plc (Amarin), incorporated on March 1, 1989, is a late-stage biopharmaceutical -company with expertise in lipid science focused on the treatment of cardiovascular disease. The Company’s product candidate is AMR101, an ultra-pure omega-3 fatty acid. It is developing AMR101 for the treatment of patients with high triglyceride levels, or hypertriglyceridemia. In September 2011, it filed a New Drug Application (NDA), with the United States Food and Drug Administration (FDA). In December 2011, it commenced patient dosing in its cardiovascular outcomes study of AMR101, titled REDUCE-IT (Reduction of Cardiovascular Events with eicosapentanoic acid (EPA) - Intervention Trial). The MARINE trial is conducted with omega-3 fatty acids in treating patients with very high triglycerides, is a Phase-III, multi-center, placebo-controlled, randomized, double-blind, 12-week study. Patients enrolled in the MARINE trial were given the option to be treated with AMR101 for a period of up to 40-weeks after their last dose in the pivotal trial. The ANCHOR trial is a multi-center, placebo-controlled, randomized, double-blind, 12-week pivotal study in patients with high triglycerides who were on optimized statin therapy. In April 2011, it reported top-line results from the ANCHOR trial. Prior to commencing the MARINE and ANCHOR trials, it conducted a pre-clinical program for AMR101, including toxicology and pharmacology studies. In addition to the MARINE and ANCHOR trials, it completed a 28-day pharmacokinetic study. It is also focusing development of other compounds based on its internal lipid science expertise.